MCID: ANT011
MIFTS: 43

Antisocial Personality Disorder malady

Category: Mental diseases

Aliases & Classifications for Antisocial Personality Disorder

About this section

Aliases & Descriptions for Antisocial Personality Disorder:

Name: Antisocial Personality Disorder 10 47 12 36 65
Psychopathic Personality Disorder 10
Dissocial Personality Disorder 10
Psychopathic Personality 10
 
Sociopathic Personality 10
Psychopath.personality 10
Asocial Personality 10

Classifications:



External Ids:

Disease Ontology10 DOID:10939
ICD1027 F60.2
ICD9CM29 301.7
MeSH36 D000987
NCIt42 C88413
UMLS65 C0003431

Summaries for Antisocial Personality Disorder

About this section
Disease Ontology:10 A personality disorder that involves a pervasive pattern of disregard for, and violation of, the rights of others that begins in childhood or early adolescence and continues into adulthood.

MalaCards based summary: Antisocial Personality Disorder, also known as psychopathic personality disorder, is related to drug dependence and schizophrenia. An important gene associated with Antisocial Personality Disorder is MAOA (Monoamine Oxidase A), and among its related pathways are Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics and putrescine degradation III. Affiliated tissues include cortex, prefrontal cortex and prostate, and related mouse phenotypes are integument and endocrine/exocrine gland.

Wikipedia:68 Antisocial personality disorder, or dissocial personality disorder (also known as psychopathy or... more...

Related Diseases for Antisocial Personality Disorder

About this section

Diseases related to Antisocial Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 330)
idRelated DiseaseScoreTop Affiliating Genes
1drug dependence29.8DRD2, MAOA, SLC6A3, SLC6A4
2schizophrenia29.1COMT, DRD2, MAOA, PRL, SLC6A3, SLC6A4
3prostatitis10.5
4cerebritis10.5
5leukemia10.4
6lymphoma10.4
7melanoma10.4
8vogt-koyanagi-harada disease10.4MAOA, SLC6A4
9impulse control disorder10.4
10conduct disorder10.4
11tympanosclerosis10.4MAOA, SLC6A4
12brachial plexus neoplasm10.4MAOA, SLC6A4
13prostate cancer10.4
14adenoma10.4
15hereditary myopathy with lactic acidosis due to iscu deficiency10.4MAOA, SLC6A4
16intermittent explosive disorder10.4MAOA, SLC6A4
17ovarian mixed germ cell neoplasm10.4MAOA, SLC6A4
18ring chromosome 14 syndrome10.3COMT, MAOA
19uterine corpus adenomatoid tumor10.3SLC6A3, SLC6A4
20neurodegeneration with optic atrophy, childhood onset10.3COMT, SLC6A4
21cystic fibrosis10.3
22arthritis10.3
23retinitis10.3
24lymphadenitis10.3MAOA, SLC6A4
25hairy cell leukemia10.3MAOA, PRL
26plasmodium malariae malaria10.3MAOA, SLC6A4
27rheumatoid arthritis10.2
28myocardial infarction10.2
29lung cancer10.2
30hiv-110.2
31breast cancer10.2
32galactosemia10.2
33aspergillosis10.2
34b-cell lymphomas10.2
35hepatitis10.2
36stomach cancer10.2
37pyelonephritis10.2
38choroiditis10.2
39presbyopia10.2
40scleritis10.2
41personality disorder10.2
42cervicitis10.2
43adenocarcinoma10.2
44lipomatosis10.2
45pancreatitis10.2
46periodontitis10.2
47lung disease10.2
48myeloid leukemia10.2
49neuropathy10.2
50hydrocele10.2

Graphical network of the top 20 diseases related to Antisocial Personality Disorder:



Diseases related to antisocial personality disorder

Symptoms for Antisocial Personality Disorder

About this section

Drugs & Therapeutics for Antisocial Personality Disorder

About this section

Drugs for Antisocial Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Naratriptanapproved, investigationalPhase 414143388-64-1, 121679-13-84440
Synonyms:
121679-13-8
AC-5013
AC1L1I6A
Amerge
Amerge, Naramig,Naratriptan
BIDD:GT0312
C07792
CHEBI:7478
CHEMBL1278
CID4440
Colatan
D08255
DB00952
InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H
L000432
 
LS-83062
MolPort-005-932-823
N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
NCGC00181786-01
Naramig
Naramig (TN)
Naratriptan
Naratriptan (INN)
Naratriptanum
S1488_Selleck
UNII-QX3KXL1ZA2
naratriptan
naratriptanum
2Vasoconstrictor AgentsPhase 4, Phase 21303
3Neurotransmitter AgentsPhase 414795
4
SerotoninPhase 4314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
5Serotonin AgentsPhase 42668
6Phase 2, Phase 3
7Omega 3 Fatty AcidNutraceuticalPhase 2, Phase 3912
8VasopressinsPhase 2260
9Natriuretic AgentsPhase 21403
10HemostaticsPhase 21082
11CoagulantsPhase 21042
12Arginine VasopressinPhase 2264
13arginineNutraceuticalPhase 2364
14
Yohimbineapproved25146-48-58969
Synonyms:
(+)-Yohimbin
(+)-Yohimbine
(+)-yohimbine
(16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester
(16alpha,17alpha)-17-Hydroxyyohimban-16-carboxylic acid methyl ester
(16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester
146-48-5
17-Hydroxy-yohimbane-16-carboxylic acid methyl ester
17-Hydroxyyohimban-16-carboxylic acid methyl ester
17alpha-Hydroxyyohimban-16alpha-carboxylic acid methyl ester
17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester
2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester
4-25-00-01237 (Beilstein Handbook Reference)
65-19-0
AC1L1S1D
APHRODINE
Actibine
Aphrodine
Aphrodyne
Aphrosol
BCBcMAP01_000032
BPBio1_000472
BRD-K35586044-001-02-6
BRD-K35586044-003-03-0
BRN 0097276
BSPBio_000428
BSPBio_001236
Baron-X
Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.
Bio1_000455
Bio1_000944
Bio1_001433
Bio2_000458
Bio2_000938
C09256
CHEBI:10093
CHEMBL15245
CID8969
Corynine
D08685
DB01392
Dayto himbin
EINECS 205-672-0
HMS1362N17
HMS1792N17
HMS1990N17
HMS2089G19
I14-13374
IDI1_002213
 
InChI=1/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12?,15?,17?,18-,19+/m0/s
Johimbin
KBio2_000576
KBio2_003144
KBio2_005712
KBio3_001031
KBio3_001032
KBioGR_000576
KBioSS_000576
LS-162738
Lopac0_001210
MLS000728591
MLS001333983
MolPort-001-794-653
NCGC00025018-05
NCGC00025018-06
NCGC00025018-07
NSC19509
Prestwick0_000584
Prestwick1_000584
Prestwick2_000584
Prestwick3_000584
Quebrachin
Quebrachine
SMP1_000320
SMR000058527
SMR000470778
SPBio_002647
STOCK1N-51304
Thybine
UNII-2Y49VWD90Q
Yocon
Yohimar
Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester
Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester
Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)- (9CI)
Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI)
Yohimbic acid methyl ester
Yohimbin
Yohimbine
Yohimbine (DCF)
Yohimbol-16alpha-carboxylic acid, methyl ester (6CI)
Yohimex
Yoman
Yovital
methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate
methyl 17alpha-hydroxyyohimban-16alpha-carboxylate
nchembio.188-comp13
nchembio705-2
trans-Quinolizidine yohimbine
15
Norepinephrineapproved59551-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
 
LT03330026
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
16
Guanfacineapproved, investigational5329110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine
Guanfacine (INN)
Guanfacine Hydrochloride
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tenex
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
17
Dopamineapproved308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
18Lisdexamfetamine Dimesylate95
19Dopamine Agents3084
20Dopamine Uptake Inhibitors925
21Neurotransmitter Uptake Inhibitors2857
22Adrenergic alpha-Agonists1300
23Central Nervous System Stimulants1721
24Adrenergic Agonists2331
25Adrenergic Agents4204
26Peripheral Nervous System Agents18510
27Detox adjuvant23
28Central Nervous System Depressants10016
29Anti-Infective Agents17220
30Anti-Infective Agents, Local984
31YohimbeNutraceutical25

Interventional clinical trials:

(show all 20)
idNameStatusNCT IDPhase
1Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment OrderTerminatedNCT00282165Phase 4
2Effect of Omega-3 Supplementation on Child Behavior ProblemsCompletedNCT02016079Phase 2, Phase 3
3Personality-targeted Interventions for Adolescent Alcohol MisuseCompletedNCT00344474Phase 2, Phase 3
4The Impact of Psychopathic Traits on the Efficacy of a Substance Use InterventionRecruitingNCT01532934Phase 2
5Working Memory Training in Adults With Substance Abuse and Executive Function Deficits.RecruitingNCT02068261Phase 2
6Vasopressin Effects on Human Social CommunicationRecruitingNCT01327027Phase 2
7Justice-Involved Veterans and Moral Reconation TherapyNot yet recruitingNCT02524171Phase 2
8Conduct Disorder in Prison: Search for Prospective and Retrospective Recurring and Contextual ElementsCompletedNCT02493088
9Matching Cognitive Remediation to Cognitive Deficits in Substance-Abusing InmatesCompletedNCT01428349
10Impaired Decision-making in AdolescentsCompletedNCT01253993Phase 0
11Psychological Mechanisms of Behavioral DysregulationCompletedNCT00352456
12The Role of Norepinephrine in Emotional ProcessingCompletedNCT00109642
13Early Exposure to Lead and Adult Antisocial OutcomesCompletedNCT00285610
14To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II DisorderCompletedNCT01263548
15Study of Children at Risk for Disruptive Behavior DisordersCompletedNCT00001233
16Antisocial Behavior: Passing From Parent to Child to GrandchildRecruitingNCT00060788
17The Effect of Prefrontal Cortex Stimulation on Antisocial and Aggressive BehaviorRecruitingNCT02427672
18ADHD: Gaps Between Patients With Alcohol-dependence and Impact on RelapseRecruitingNCT02364817
19Mental Health Related to School Dropout in LuxembourgEnrolling by invitationNCT01354236
20The Effect of Repeated Prefrontal Cortex Stimulation on Antisocial and Aggressive BehaviorNot yet recruitingNCT02674516

Search NIH Clinical Center for Antisocial Personality Disorder


Cochrane evidence based reviews: antisocial personality disorder

Genetic Tests for Antisocial Personality Disorder

About this section

Anatomical Context for Antisocial Personality Disorder

About this section

MalaCards organs/tissues related to Antisocial Personality Disorder:

33
Cortex, Prefrontal cortex, Prostate, Breast, Liver, Lung, Skin

Animal Models for Antisocial Personality Disorder or affiliated genes

About this section

MGI Mouse Phenotypes related to Antisocial Personality Disorder:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107718.5ALDH2, DRD2, PRL, SLC6A3, SLC6A4
2MP:00053797.7ALDH2, COMT, DRD2, PRL, SLC6A3, SLC6A4
3MP:00053867.2ALDH2, COMT, DRD2, MAOA, PRL, SLC6A3
4MP:00053767.2ALDH2, COMT, DRD2, MAOA, PRL, SLC6A3
5MP:00036316.9ALDH2, COMT, DRD2, MAOA, PRL, SLC6A3

Publications for Antisocial Personality Disorder

About this section

Articles related to Antisocial Personality Disorder:

(show top 50)    (show all 339)
idTitleAuthorsYear
1
The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. (25728532)
2015
2
Durable thrombosis in a rat model of arteriovenous malformation treated with radiosurgery and vascular targeting. (24180569)
2014
3
Natural Products for Treatment of Alzheimer's Disease and Related Diseases: Understanding their Mechanism of Action. (24381527)
2013
4
Anesthesia under cardiopulmonary bypass for video assisted thoracoscopic wedge resection in patient with spontaneous pneumothorax and contralateral post-tuberculosis destroyed lung. (24024004)
2013
5
Parafoveal scotoma progression in glaucoma: humphrey 10-2 versus 24-2 visual field analysis. (23697959)
2013
6
Linking I^-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer. (24296312)
2013
7
Association between root resorption incident to orthodontic treatment and treatment factors. (23142948)
2013
8
Neuropathic pain components are common in patients with painful cervical radiculopathy, but not in patients with nonspecific neck-arm pain. (23364214)
2013
9
Exome sequencing identifies a COL14A1 mutation in a large Chinese pedigree with punctate palmoplantar keratoderma. (22972947)
2012
10
Ultra-wide-field autofluorescence imaging in non-traumatic rhegmatogenous retinal detachment. (22722489)
2012
11
The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. (22878533)
2012
12
Hepatitis: hepatitis E and decompensated chronic liver disease. (22733353)
2012
13
Pacinian neurofibroma: a rare neurogenic tumor. (21393958)
2011
14
Surgical resection of the inferior vena cava for leiomyosarcoma. (20494550)
2010
15
The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. (19721860)
2009
16
Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). (19923897)
2009
17
Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. (19190325)
2009
18
Amino acid modifications on tRNA. (18604446)
2008
19
Regulation of TLR2 expression by prostaglandins in brain glia. (18523308)
2008
20
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. (18281615)
2008
21
Histiocytic sarcoma: PET-CT evaluation of a rare entity. (18982475)
2008
22
Pharmacological therapy of Cushing's syndrome: drugs and indications. (17504182)
2007
23
The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs. (16861115)
2006
24
Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. (16775307)
2006
25
Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment. (16205966)
2006
26
Pathogen recognition and signalling in the Drosophila innate immune response. (16697918)
2006
27
Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension. (16135938)
2005
28
Mutation spectrum and founder chromosomes for the ABCA4 gene in South African patients with Stargardt disease. (15161829)
2004
29
A pedigree with Pendred syndrome: case report and discussion on hereditary hearing loss. (15513511)
2004
30
Coadministration of multidrug therapy to achieve lipid goals. (15467020)
2004
31
Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. (12832328)
2003
32
ATP7A gene mutations in 16 patients with Menkes disease and a patient with occipital horn syndrome. (11241493)
2001
33
Leukocyte-endothelial cell interactions in diabetic retina after transient retinal ischemia. (10956257)
2000
34
Delayed mustard gas keratopathy: clinical findings and confocal microscopy. (10577594)
1999
35
Requirement of protein kinase C zeta for stimulation of protein synthesis by insulin. (9271396)
1997
36
cynDAZLA: a cynomolgus monkey homologue of the human autosomal DAZ gene. (9239736)
1997
37
Vitamin E succinate inhibits proliferation of BT-20 human breast cancer cells: increased binding of cyclin A negatively regulates E2F transactivation activity. (9205075)
1997
38
Cumulative trauma disorders: an ergonomic approach for prevention. (9470570)
1997
39
The effects of modulation of the L-arginine-nitric oxide pathway on myocardial stunning following repetitive coronary occlusion in dogs. (8857235)
1995
40
Lipid mobilization, physiopathological and pharmacological aspects]. (7755346)
1995
41
Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients. (8415900)
1993
42
Immunoglobulin kappa light chain germ-line transcripts in human precursor B lymphocytes. (1446707)
1992
43
Purification of alpha and beta subunits of phosphorylase-b-kinase in human liver and cardiac muscle by affinity chromatography and immunodetection. (1770779)
1991
44
Localization of blood coagulation factors and fibrinolysis factors within lymphoid germinal centers in human lymph nodes. (1680835)
1991
45
Transsexualism. (2064661)
1991
46
Serous papillary adenocarcinoma of the tunica vaginalis of the testis with metastasis. (1991312)
1991
47
Aggressive treatment with pulse methylprednisolone or plasma exchange is justified in rapidly progressive glomerulonephritis. (6878261)
1983
48
Iridocyclitis: incidence, distribution and health service usage. (7190479)
1980
49
Infantile neuroaxonal dystrophy and related disorders. (80340)
1978
50
Trisomy 22 in a newborn girl with multiple malformations. (730543)
1978

Variations for Antisocial Personality Disorder

About this section

Expression for genes affiliated with Antisocial Personality Disorder

About this section
Search GEO for disease gene expression data for Antisocial Personality Disorder.

Pathways for genes affiliated with Antisocial Personality Disorder

About this section

Pathways related to Antisocial Personality Disorder according to GeneCards Suite gene sharing:

(show all 13)
idSuper pathwaysScoreTop Affiliating Genes
19.8MAOA, SLC6A4
29.6ALDH2, MAOA
3
Show member pathways
9.6ALDH2, MAOA
4
Show member pathways
9.4DRD2, MAOA, SLC6A3
5
Show member pathways
9.4MAOA, SLC6A3, SLC6A4
6
Show member pathways
9.3COMT, MAOA
79.3COMT, MAOA
8
Show member pathways
9.3COMT, SLC6A4
9
Show member pathways
8.8ALDH2, COMT, MAOA
10
Show member pathways
8.8ALDH2, COMT, MAOA
11
Show member pathways
8.4ALDH2, COMT, MAOA, SLC6A3
12
Show member pathways
8.4ALDH2, COMT, MAOA, SLC6A3
13
Show member pathways
8.2COMT, DRD2, MAOA, SLC6A3, SLC6A4

GO Terms for genes affiliated with Antisocial Personality Disorder

About this section

Biological processes related to Antisocial Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1response to ethanolGO:00454719.8DRD2, SLC6A3
2neurotransmitter catabolic processGO:00421359.8COMT, MAOA
3locomotory behaviorGO:00076269.7DRD2, SLC6A3
4neurotransmitter biosynthetic processGO:00421369.3ALDH2, COMT, MAOA
5female pregnancyGO:00075659.1COMT, PRL
6response to drugGO:00424938.2COMT, DRD2, SLC6A3, SLC6A4

Sources for Antisocial Personality Disorder

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet